Literature DB >> 6633617

Clinical epidemiology of toxic-oil syndrome. Manifestations of a New Illness.

E M Kilbourne, J G Rigau-Perez, C W Heath, M M Zack, H Falk, M Martin-Marcos, A de Carlos.   

Abstract

An epidemic of a new illness involving multiple organ systems began in Spain in May 1981, with 19,828 cases and 315 deaths reported by June 1, 1982. An epidemiologic investigation has linked the occurrence of illness with ingestion of an unlabeled, illegally marketed cooking oil. To elucidate the natural history of this illness, we reviewed the medical records of 121 patients in one severely affected town 100 km northwest of Madrid. The findings during the first week after onset were those of a febrile, pneumonia-like illness. Gastrointestinal findings and striking eosinophilia became prominent later in the first month. Although the disease followed a self-limited course in many patients, severe neuromuscular manifestations (myalgia severe enough to restrict movement, motor deficits, atrophy of major muscle groups, and contractures of the jaw and extremities) occurred late in the course of the illness (an average of 96 days after onset) in 23 per cent of the patients. The onset of disease early in the epidemic and particularly severe initial systemic findings were associated with progression to neuromuscular illness.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6633617     DOI: 10.1056/NEJM198312083092302

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  16 in total

1.  Participation of eosinophils in the toxic oil syndrome.

Authors:  R M Ten; G M Kephart; M Posada; I Abaitua; L Soldevilla; E M Kilbourne; S L Dunnette; G J Gleich
Journal:  Clin Exp Immunol       Date:  1990-11       Impact factor: 4.330

Review 2.  Clinical features, pathogenesis and management of drug-induced rhabdomyolysis.

Authors:  C Köppel
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Mar-Apr

Review 3.  Epidemiology of scleroderma.

Authors:  A J Silman
Journal:  Ann Rheum Dis       Date:  1991-11       Impact factor: 19.103

4.  Investigations of selected historically important syndromic outbreaks: impact and lessons learned for public health preparedness and response.

Authors:  Richard A Goodman; Joseph M Posid; Tanja Popovic
Journal:  Am J Public Health       Date:  2012-02-16       Impact factor: 9.308

5.  Abnormalities of the coronary arteries, neural structures and conduction system of the heart observed postmortem in the eosinophilia-myalgia syndrome, with a discussion of comparative findings from the toxic oil syndrome.

Authors:  T N James
Journal:  Trans Am Clin Climatol Assoc       Date:  1991

6.  Case series and exposure series: the role of studies without controls in providing information about the etiology of injury or disease.

Authors:  P Cummings; N S Weiss
Journal:  Inj Prev       Date:  1998-03       Impact factor: 2.399

7.  Drug-induced pulmonary arterial hypertension: a primer for clinicians and scientists.

Authors:  Mark E Orcholski; Ke Yuan; Charlotte Rajasingh; Halley Tsai; Elya A Shamskhou; Navneet K Dhillon; Norbert F Voelkel; Roham T Zamanian; Vinicio A de Jesus Perez
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-02-08       Impact factor: 5.464

8.  Effects of dietary oil related to the toxic oil syndrome on the lipids of guinea pig liver microsomes.

Authors:  E de la Casa; N Pérez-González; C Sánchez-Bernal; M Llanillo
Journal:  Lipids       Date:  1995-06       Impact factor: 1.880

9.  Bioassay screening for toxicants in oil samples from the toxic-oil syndrome outbreak in Spain.

Authors:  W E Turner; R H Hill; W H Hannon; J T Bernert; E M Kilbourne; D D Bayse
Journal:  Arch Environ Contam Toxicol       Date:  1985-05       Impact factor: 2.804

10.  L-tryptophan implicated in human eosinophilia-myalgia syndrome causes fasciitis and perimyositis in the Lewis rat.

Authors:  L J Crofford; J I Rader; M C Dalakas; R H Hill; S W Page; L L Needham; L S Brady; M P Heyes; R L Wilder; P W Gold
Journal:  J Clin Invest       Date:  1990-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.